title: Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
abstract: Ser/Thr protein kinase CK2 regulates multiple processes that play important roles in the sensitivity of cancer to epidermal growth factor receptor targeting therapeutics, including PI3K-Akt-mTOR signaling, Hsp90 activity, and inhibition of apoptosis. We hypothesized that top-down inhibition of EGFR, combined with lateral suppression of multiple oncogenic pathways by targeting CK2, would create a pharmacologic synthetic lethal event and result in an improved cancer therapy compared to EGFR inhibition alone. This hypothesis was tested by combining CX-4945, a first-in-class clinical stage inhibitor of CK2, with the EGFR tyrosine kinase inhibitor, erlotinib, in vitro and in vivo in models of non-small cell lung carcinoma, NCI-H2170, and squamous cell carcinoma, A431. Our results demonstrate that combination of CX-4945 with erlotinib results in enhanced attenuation of the PI3K-Akt-mTOR pathway. We also observed an increase in apoptosis, synergistic killing of cancer cells in vitro, as well as improved antitumor efficacy in vivo. Taken together, these data position CK2 as a valid pharmacologic target for drug combinations and support further evaluation of CX-4945 in combination with EGFR targeting agents.
authors.affiliation: Cylene Pharmaceuticals, San Diego, CA 92121, United States.
authors.forename: Joshua
authors.initials: J
authors.lastname: Bliesath
authors.forename: Nanni
authors.initials: N
authors.lastname: Huser
authors.forename: Mayuko
authors.initials: M
authors.lastname: Omori
authors.forename: Daniel
authors.initials: D
authors.lastname: Bunag
authors.forename: Chris
authors.initials: C
authors.lastname: Proffitt
authors.forename: Nicole
authors.initials: N
authors.lastname: Streiner
authors.forename: Caroline
authors.initials: C
authors.lastname: Ho
authors.forename: Adam
authors.initials: A
authors.lastname: Siddiqui-Jain
authors.forename: Sean E
authors.initials: SE
authors.lastname: O'Brien
authors.forename: John K C
authors.initials: JK
authors.lastname: Lim
authors.forename: David M
authors.initials: DM
authors.lastname: Ryckman
authors.forename: Kenna
authors.initials: K
authors.lastname: Anderes
authors.forename: William G
authors.initials: WG
authors.lastname: Rice
authors.forename: Denis
authors.initials: D
authors.lastname: Drygin
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D047390:Casein Kinase II / Q000037:antagonists & inhibitors*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D051379:Mice; D009287:Naphthyridines / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010619:Phenazines; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology*; D011799:Quinazolines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*; D058570:TOR Serine-Threonine Kinases / Q000502:physiology*
chemical_list: D047390:Casein Kinase II; D066246:ErbB Receptors; D000069347:Erlotinib Hydrochloride; D009287:Naphthyridines; D010619:Phenazines; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D011799:Quinazolines; D058570:TOR Serine-Threonine Kinases; C555142:silmitasertib; C546842:MTOR protein, human